Story
Zoetis Stock Rebounds Despite Drastic Cut to 2026 Financial Outlook

Shares of Zoetis (ZTS) recovered from an intraday low to trade higher on Tuesday, even after the animal health giant significantly lowered its full-year financial guidance due to mounting pressure in the U.S. pet care market. The company's mixed second-quarter earnings report, released before the market open, revealed a slight profit beat but a substantial cut to its 2026 forecast.
A Mixed Report and Slashed Outlook
Zoetis reported second-quarter adjusted earnings per share (EPS) of $1.87, narrowly beating the analyst consensus of $1.86. However, revenue came in flat year-over-year at approximately $2.5 billion, missing estimates.
The more significant development was the sharp downward revision to its full-year 2026 forecast. The company now expects:
- Adjusted EPS: $6.15 to $6.25, far below the consensus estimate of $6.87.
- Annual Revenue: $9.12 billion to $9.32 billion, a reduction from its prior range of $9.68 billion to $9.96 billion.
Headwinds in the US Pet Market
AdAccording to CEO Kristin Peck, the guidance reduction was driven by challenges in the company's largest segment, companion animals. U.S. revenue for this unit declined 7% during the quarter. The company cited fewer visits to veterinary clinics, increased price sensitivity among pet owners, and intensifying competition as the primary factors behind the slowdown.
This domestic weakness was partially offset by stronger performance abroad, with international revenue rising 6%. The company also announced the appointment of Jay Saccaro, formerly of GE HealthCare, as its new Executive Vice President, CFO, and COO, effective August 17.
Market Reaction and Context
Despite the negative outlook, the stock's rebound may reflect investor sentiment that the bad news was already priced in. Shares of Zoetis have fallen by roughly half over the past 12 months and recently touched a 52-week low. After an initial selloff, some investors may be viewing the stock's compressed valuation as an opportunity.
The stock's performance stands in contrast to peer IDEXX Laboratories, which recently raised its own annual profit forecast. Zoetis experienced significant intraday volatility, opening higher before falling to a session low of $73.72 and then climbing into positive territory, highlighting the market's struggle to digest the competing signals of a minor earnings beat against a severe guidance cut.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.